Conference
Abstract CT149: BOLD-100-001 (TRIO039): a phase 1b/2a dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced colorectal cancer: interim efficacy, safety and tolerability analysis
Abstract
Abstract
Background: BOLD-100 is a first-in-class ruthenium-based anticancer agent in Phase 1b/2a clinical development for the treatment of advanced gastrointestinal (GI) cancers in combination with FOLFOX. BOLD-100 demonstrated synergy in established preclinical models in combination with various anticancer therapies, particularly in resistant cell lines. In the first interim analysis of the phase 1b dose-escalation component …
Authors
Spratlin J; O'Kane G; Oh D-Y; Rha SY; McWhirter E; Elimova E; Kavan P; Choi MK; Kim DW; Goodwin R
Volume
83
Pagination
pp. ct149-ct149
Publisher
American Association for Cancer Research (AACR)
Publication Date
April 14, 2023
DOI
10.1158/1538-7445.am2023-ct149
Conference proceedings
Cancer Research
Issue
8_Supplement
ISSN
0008-5472